State Street Corp Aptinyx Inc. Transaction History

State Street Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	BUY	$2.27 - $3.62 $19,860 - $31,671	8,749 Added 6.76%	138,251 $314,000
Q2 2021 Aug 16, 2021	SELL	$2.39 - $3.5 $843,856 - $1.24 Million	-353,078 Reduced 73.16%	129,502 $366,000
Q1 2021 May 17, 2021	BUY	$2.86 - $4.33 $172,458 - $261,099	60,300 Added 14.28%	482,580 $1.45 Million
Q4 2020 Feb 16, 2021	BUY	$2.93 - $4.3 $326,050 - $478,504	111,280 Added 35.78%	422,280 $1.46 Million
Q3 2020 Nov 10, 2020	BUY	$3.05 - $4.99 $122,915 - $201,097	40,300 Added 14.89%	311,000 $1.05 Million
Q2 2020 Aug 14, 2020	BUY	$1.99 - $4.4 $538,693 - $1.19 Million	270,700 New	270,700 $1.13 Million

Ticker APTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,715,696
Description
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic pe...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.